Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Sartor C, Arpinati M, Chirumbolo G, Dozza L, Cristiano G, Nanni J, Marconi G, Robustelli V, Vigliotta I, Parisi S, Terragna C, Testoni N, Paolini S, Martinelli G, Curti A, Cavo M, Papayannidis C.
Sartor C, et al. Among authors: cavo m.
Hematol Oncol. 2022 Oct;40(4):734-742. doi: 10.1002/hon.3029. Epub 2022 Jun 5.
Hematol Oncol. 2022.
PMID: 35618655